Fund shareholders of Ionis Pharmaceuticals Inc
ISIN US4622221004 · United States · LEI 549300SI4ZGLG0BLUZ92
- Fund shareholders
- 436
- Of which ETFs
- 100 336 other funds
- Value held
- 6.6B $ 346.9M SEK · 4M €
- Share of capital
- 51.7 % of 166.2M shares on Jul 23, 2026
436 funds hold this company. This table lists the 431 that declare it in a regulatory filing. The other 5 publish their holdings in their own reports. They are not in the table.
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| AST PGIM Aggressive Multi-Asset Portfolio Advanced Series Trust | 322 | 24.2K $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| T. Rowe Price Spectrum Conservative Allocation Fund T. ROWE PRICE SPECTRUM FUNDS II, INC. | 280 | 22.7K $ | 0.00 % | 0.00 % | as of Feb 28, 2026 ↗ |
| Motley Fool Momentum Factor ETF RBB Fund, Inc. | 274 | 22.2K $ | 0.46 % | 0.00 % | as of Feb 28, 2026 ↗ |
| AZL DFA U.S. Core Equity Fund Allianz Variable Insurance Products Trust | 258 | 19.4K $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| AB US Equity ETF AB Active ETFs, Inc. | 220 | 17.9K $ | 0.00 % | 0.00 % | as of Feb 28, 2026 ↗ |
| RiverNorth Patriot ETF Elevation Series Trust | 216 | 16.2K $ | 0.43 % | 0.00 % | as of Mar 31, 2026 ↗ |
| E*TRADE No Fee Total Market Index Fund E Trade Trust | 205 | 15.3K $ | 0.02 % | 0.00 % | as of Apr 30, 2026 ↗ |
| Invesco QQQ Hedged Advantage ETF Invesco Actively Managed Exchange-Traded Fund Trust | 179 | 13.4K $ | 0.11 % | 0.00 % | as of Apr 30, 2026 ↗ |
| LargeCap Value Fund III Principal Funds, Inc | 163 | 12.2K $ | 0.00 % | 0.00 % | as of Apr 30, 2026 ↗ |
| MidCap Value Fund I Principal Funds, Inc | 158 | 11.8K $ | 0.00 % | 0.00 % | as of Apr 30, 2026 ↗ |
| Goldman Sachs MarketBeta(R) Russell 1000 Value Equity ETF Goldman Sachs ETF Trust | 153 | 12.4K $ | 0.00 % | 0.00 % | as of Feb 28, 2026 ↗ |
| Sector Rotation Fund Meeder Funds | 152 | 11.4K $ | 0.03 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Avantis Total Equity Markets ETF American Century ETF Trust | 144 | 11.7K $ | 0.00 % | 0.00 % | as of Feb 28, 2026 ↗ |
| Strategic Allocation: Conservative Fund American Century Strategic Asset Allocations Inc | 137 | 10.2K $ | 0.00 % | 0.00 % | as of Apr 30, 2026 ↗ |
| Avantis Inflation Focused Equity ETF American Century ETF Trust | 129 | 10.5K $ | 0.12 % | 0.00 % | as of Feb 28, 2026 ↗ |
| BlackRock Global Allocation Portfolio BlackRock Series Fund, Inc. | 106 | 8K $ | 0.01 % | 0.00 % | as of Mar 31, 2026 ↗ |
| AZL Russell 1000 Value Index Fund Allianz Variable Insurance Products Trust | 101 | 7.6K $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Select Pharmaceuticals Portfolio Fidelity Select Portfolios | 100 | 8.1K $ | 0.00 % | 0.00 % | as of Feb 28, 2026 ↗ |
| THRIVENT MODERATELY CONSERVATIVE ALLOCATION FUND Thrivent Mutual Funds | 98 | 7.3K $ | 0.00 % | 0.00 % | as of Apr 30, 2026 ↗ |
| Columbia Research Enhanced Value ETF Columbia ETF Trust I | 87 | 6.5K $ | 0.00 % | 0.00 % | as of Apr 30, 2026 ↗ |
| VIP Hedged Equity Portfolio Variable Insurance Products Fund VI | 71 | 5.3K $ | 0.04 % | 0.00 % | as of Mar 31, 2026 ↗ |
| SA Multi-Managed Mid Cap Value Portfolio SEASONS SERIES TRUST | 70 | 5.3K $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Kennedy Capital Small Cap Growth Fund INVESTMENT MANAGERS SERIES TRUST II | 59 | 4.4K $ | 0.89 % | 0.00 % | as of Mar 31, 2026 ↗ |
| T. Rowe Price Moderate Allocation Portfolio T. ROWE PRICE EQUITY SERIES, INC. | 47 | 3.5K $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| T. Rowe Price Active Core U.S. Equity ETF T. Rowe Price Exchange-Traded Funds, Inc. | 43 | 3.2K $ | 0.03 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Avantis Responsible U.S. Equity ETF American Century ETF Trust | 38 | 3.1K $ | 0.00 % | 0.00 % | as of Feb 28, 2026 ↗ |
| Columbia Research Enhanced Mid Cap ETF Columbia ETF Trust I | 38 | 2.9K $ | 0.09 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Goldman Sachs MSCI World Private Equity Return Tracker ETF Goldman Sachs ETF Trust | 26 | 2.1K $ | 0.01 % | 0.00 % | as of Feb 28, 2026 ↗ |
| CAIXABANK MULTISALUD, FI CAIXABANK ASSET MANAGEMENT SGIIC, S.A. | 3.5M € | 0.53 % | as of Dec 31, 2025 ↗ | ||
| GESTION BOUTIQUE VI, FI GESTION BOUTIQUE VI / KALDI ANDBANK WEALTH MANAGEMENT, SGIIC, S.A.U. | 357K € | 3.68 % | as of Dec 31, 2025 ↗ | ||
| A&P LIFESCIENCE FUND, FI WELZIA MANAGEMENT, SGIIC, S.A. | 168.4K € | 4.58 % | as of Dec 31, 2025 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| Horizon Kinetics Medical ETF Listed Funds Trust | 4.73 % | as of Mar 31, 2026 ↗ |
| A&P LIFESCIENCE FUND, FI WELZIA MANAGEMENT, SGIIC, S.A. | 4.58 % | as of Dec 31, 2025 ↗ |
| HealthInvest Small & Mid Cap Healthcare Atle Fund Management AB | 3.98 % | as of Mar 31, 2026 ↗ |
| AlphaCentric Life Sciences and Healthcare Fund MUTUAL FUND SERIES TRUST | 3.74 % | as of Mar 31, 2026 ↗ |
| GESTION BOUTIQUE VI, FI GESTION BOUTIQUE VI / KALDI ANDBANK WEALTH MANAGEMENT, SGIIC, S.A.U. | 3.68 % | as of Dec 31, 2025 ↗ |
| Tweedy, Browne International Value Fund Tweedy, Browne Fund Inc. | 3.17 % | as of Mar 31, 2026 ↗ |
| Baron Health Care Fund BARON SELECT FUNDS | 2.81 % | as of Mar 31, 2026 ↗ |
| Tweedy, Browne Value Fund Tweedy, Browne Fund Inc. | 2.79 % | as of Mar 31, 2026 ↗ |
| Eventide Healthcare & Life Sciences Fund MUTUAL FUND SERIES TRUST | 2.72 % | as of Mar 31, 2026 ↗ |
| Invesco Biotechnology & Genome ETF Invesco Exchange-Traded Fund Trust | 2.49 % | as of Apr 30, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Shareholders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q2 | 422 | +29 | 85,444,539 | +5.7 % |
| 2026Q1 | 393 | +45 | 80,814,443 | +5.3 % |
| 2025Q4 | 348 | +62 | 76,715,982 | -3.1 % |
| 2025Q3 | 286 | +12 | 79,201,702 | -1.0 % |
| 2025Q2 | 274 | -12 | 79,971,398 | +0.1 % |
| 2025Q1 | 286 | -17 | 79,920,146 | +7.6 % |
| 2024Q4 | 303 | +4 | 74,303,125 | +10.4 % |
| 2024Q3 | 299 | -10 | 67,280,894 | +3.7 % |
| 2024Q2 | 309 | +10 | 64,888,088 | +5.0 % |
| 2024Q1 | 299 | +15 | 61,777,585 | -4.9 % |
| 2023Q4 | 284 | 64,944,400 |
Institutional managers
483 managers declare this company to the SEC (Form 13F). The table shows the 25 largest.
| Manager | Shares | Value | |
|---|---|---|---|
| FMR LLC | 24,556,637 | 1.8B $ | as of Mar 31, 2026 |
| Capital World Investors | 21,186,369 | 1.6B $ | as of Mar 31, 2026 |
| BlackRock, Inc. | 10,442,476 | 784.1M $ | as of Mar 31, 2026 |
| WELLINGTON MANAGEMENT GROUP LLP | 6,391,816 | 480M $ | as of Mar 31, 2026 |
| T. Rowe Price Investment Management, Inc. | 6,159,027 | 462.5K $ | as of Mar 31, 2026 |
| TWO SIGMA INVESTMENTS, LP | 5,857,629 | 439.8M $ | as of Mar 31, 2026 |
| STATE STREET CORP | 3,995,564 | 300M $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 3,984,332 | 305.2M $ | as of Mar 31, 2026 |
| ROYAL BANK OF CANADA | 3,801,815 | 285.5M $ | as of Mar 31, 2026 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 3,025,251 | 227.2K $ | as of Mar 31, 2026 |
| JPMORGAN CHASE & CO | 2,363,567 | 171.4M $ | as of Mar 31, 2026 |
| Tweedy, Browne Co LLC | 2,275,625 | 170.9M $ | as of Mar 31, 2026 |
| Artisan Partners Limited Partnership | 2,058,308 | 154.6M $ | as of Mar 31, 2026 |
| BAKER BROS. ADVISORS LP | 2,047,727 | 153.8M $ | as of Mar 31, 2026 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 1,979,669 | 148.7M $ | as of Mar 31, 2026 |
| Deep Track Capital, LP | 1,950,000 | 146.4M $ | as of Mar 31, 2026 |
| Bellevue Group AG | 1,818,665 | 136.6M $ | as of Mar 31, 2026 |
| GOLDMAN SACHS GROUP INC | 1,699,847 | 127.6M $ | as of Mar 31, 2026 |
| AMERICAN CENTURY COMPANIES INC | 1,663,803 | 124.9M $ | as of Mar 31, 2026 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,583,266 | 118.9M $ | as of Mar 31, 2026 |
| FRANKLIN RESOURCES INC | 1,575,023 | 118.3M $ | as of Mar 31, 2026 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1,475,632 | 110.8M $ | as of Mar 31, 2026 |
| Pictet Asset Management Holding SA | 1,434,995 | 107.1M $ | as of Mar 31, 2026 |
| SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 1,404,033 | 105.4M $ | as of Mar 31, 2026 |
| Invesco Ltd. | 1,277,358 | 95.9M $ | as of Mar 31, 2026 |
Declared shareholders of Ionis Pharmaceuticals Inc
There are 3 beneficial ownership filings. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| Capital World Investors | 12.80 % | 21,186,369 | as of Mar 31, 2026 · SCHEDULE 13G |
| Vanguard Capital Management | 5.05 % | 8,344,732 | as of Mar 31, 2026 · SCHEDULE 13G |
| T. Rowe Price Investment Management, Inc. | 3.70 % | 6,159,027 | as of Mar 31, 2026 · SCHEDULE 13G |
Funds holding the debt of Ionis Pharmaceuticals Inc
55 funds declare 74 bond lines of this company. The table shows the 25 largest holdings. The amount is the one the fund files. It is not a share of the debt, because no regulator publishes the amount outstanding in open access.
Cite this page
Titelia. "Fund shareholders of Ionis Pharmaceuticals Inc". https://titelia.com/en/stocks/ionis-pharmaceuticals-inc-US4622221004